semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Alveolar Osteitis Patients who have one or more of the following in addition to severe pain, which occur within and around the socket 1-3 days after extraction and do not decrease with pain killers With a partially or completely disintegrated blood clot in the socket With exposed bone that gives a dark gray appearance With bad odor  Who does not want to be volunteer for the study Smokers During pregnancy or lactation Has a chronic systemic disorder that will affect recovery Has hematological disorder Cooperation cannot be established Previously received radiotherapy or chemotherapy Patients using oral contraceptives
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-40.0,  Cervicogenic Headache Headache frequency of at least 1 per week for a minimum of 3 months Secondary Headache (cervical spine dysfunction) International Classification of headache Disorder: 1. Pain localized in the neck and occiput, which can spread to other areas in the head, such as forehead, orbital region, temples, vertex, or ears, usually unilateral. 2. Pain is precipitated or aggravated by specific neck movements or sustained postures. 3. At least one of the following: 1. Resistance to or limitation of passive neck movements 2. Changes in neck muscle contour, texture, tone, or response to active and passive stretching and contraction 3. Abnormal tenderness of neck musculature  Other types of headache Trigger points of upper cervical muscles Congenital conditions of cervical spine Cervical Disc herniation Fracture Cervical Artery disease Red flags of Thrust Joint Manipulation
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infant Cerebral Palsy Neonatal For the parents: Parents of children under 24 months of age at high risk of cerebral palsy who have given their oral consent. Children at high risk of cerebral palsy are defined as  Premature children ≤ 31 WG + 6 days or birth weight less than 1000g Children who have had a stroke or stage 2 or 3 hypoxia-ischemia according to the Sarnat classification. The selection of parents may be retrospective with less than 24 months since hospital discharge. 2. For the health professionals: Physiotherapists, psychomotricians, psychologists and doctors involved in the care of children at high risk of cerebral palsy  A person who is physically or cognitively unable to participate in a one-on-one interview or who does not have a sufficient command of the French language Parents aged <18 years Parents in protective custody Parents of children with major orthopedic or traumatic disorders unrelated to the high risk of cerebral palsy Parents of a child with a genetic disease
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Plasma Cell Myeloma Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 Neutrophil values > 1,000/uL Diagnosis of multiple myeloma: on maintenance or continued treatment Show no signs of comorbidities, myeloma symptoms, or treatment side effects that would put them in danger when participating in the study according to the physician's discretion Able to understand and comply with study instructions, including willing to purchase and consume study beverage daily if in intervention arm or, avoid regular consumption of fermented dairy foods (kefir, yogurt, lassi, etc.) if in the control arm Understand the investigational nature of the study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure  Allergies to milk Lactose intolerance Current habitual (> 3 times per week) consumption of yogurt, kefir, lassi, over-the-counter probiotic dietary supplements Chronic inflammatory bowel disease Autologous stem cell transplantation or chimeric antigen receptor (CAR)-T cell therapy within the last 6 months Prior allogeneic stem cell transplantation Major comorbidities that would cause danger to the patient when participating in the study Pregnant or nursing female participants Unwilling or unable to follow protocol requirements Any condition which in the investigator's opinion deems the participant an unsuitable candidate to take part in study intervention
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Neuroendocrine Tumors Metastatic, or unresectable, histologically confirmed well-differentiated grade 1 and 2 neuroendocrine tumor with a positive gallium 68 Dotatate scan within 6 months prior to study enrollment Baseline CT scan or MRI with measurable progressive disease based on Failure of at least one prior systemic cancer treatment for this diagnosis Recovered from AEs of previously administered therapeutic agents to Grade 2 or less toxicity according to CTCAE version 5.0 ECOG performance status ≤2 normal organ and marrow function  Prior exposure to Lutetium Lu 177 Dotatate History of allergic reactions attributed to compounds of similar chemical or biologic composition to Telotristat or Lutetium Lu 177 Dotatate Presence of unstable angina or myocardial infarction NYHA Class III or IV heart failure uncontrolled angina history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities Pregnant or lactating women Women of childbearing potential or male patients of reproductive potential Any other significant medical or psychiatric condition, currently uncontrolled by treatment, which may interfere with completion of the study
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-8.0,  Dental Pulp Cavity Primary molars with at least one of the following signs and symptoms were eligible and were included in the study badly decayed with signs of irreversible pulpitis necrosis and chronic infection such as: pain or tenderness to percussion and palpation, abscess, fistula-opening, gingival swelling, grade II and greater pathological tooth mobility, evidence of periapical/bifurcation radiolucency, All the teeth included, had physiological root resorption of less than one third of the root  Teeth showing radiographic evidence of excessive internal or external root resorption perforated pulpal floor excessive bone loss in furcation area involving the underlying tooth germ non restorable teeth were excluded from the study
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Osteonecrosis of the Jaw, Bisphosphonate Induced Osteonecrosis of the Jaw, Bisphosphonate Related Diagnosis of stage I or stage II medication related osteonecrosis of the jaws (MRONJ) according to the 2014 AAOMS position paper  Coexistence of any medical or social condition that prevents proper adherence to treatment or follow-ups (dependent patients without adequate socio-familiar support, drug addiction, severe psychiatric illness, terminal disease with life expectancy less than 3 months) Coexistence of Brown's Tumor, Paget's Disease or other bone diseases with the exception of Osteoporosis or bone metastases
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Coxarthrosis; Primary Coxarthrosis; Secondary Patient with primary or secondary hip arthritis, at stage II to III of the radiological classification of Tönnis and for whom total hip replacement is indicated by surgeon Signed consent Patient beneficiary of a social security plan  Patient Under 18 Patient Under protective measure (guardianship, curatorship) or unable to consent Patient requiring revision THR Patient with geographic mobility plan before the end of the follow-up Symptomatic contralateral hip Symptomatic dorsolumbar rachis Pelvis or spine surgery planed during the follow-up Pregnant or nursing woman
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Stress Fracture of Tibia or Fibula Soldiers actively enlisted in the U.S. Army attached to basic training unit at Fort Jackson Soldiers diagnosed with a tibial diaphyseal BSI requiring convalescent leave Skeletally mature Willing to self-administer study medication Desire to continue their military commitment  History of any form of cancer Currently pregnant Paget's disease of bone Unexplained elevations of alkaline phosphatase (elevations in alkaline phosphatase may signal undiagnosed Paget's disease of bone) Pediatric and young adult patients with open epiphyses Prior external beam or implant radiation therapy involving the skeleton Recent (within the last 6 months) urolithiasis (kidney stones) Elevated serum calcium, alkaline phosphatase or uric acid Orthostatic hypotension
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Disease Patients aged > 18 years resident in Campania Region Patients diagnosed with metastatic disease candidates for radiotherapy Metastatic patients candidates for radiotherapy re-treatment Oligometastatic patients candidates for radiotherapy; Patients who have given their consent  Patients aged < 18 years Patients who are unable to express consent to sensitive data and radiant treatment
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 4.0-7.0,  Reversible Pulpitis Aged 4 to 7 years , in good general health and mentally free The parents provided written informed consent Cariously exposed primary molars with reversible pulpitis Teeth should be vital Restorable teeth Hemostasis achieved after complete pulpotomy  With systemic disease Physical or mental disability Unable to attend follow-up visits Refusal of participation Previously accessed teeth History of spontaneous or prolonged pain Swelling, tenderness to percussion or palpation, or pathological mobility Pre-operative radiographic pathology such as resorption(internal or external),per-radicular or furcation radiolucency Haemorrhage control is unachievable after pulpotomy
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Low Back Pain Acute Pain patients aged>18 years old initiation of acute low back pain in the 10 days prior to study entry and functionally impairing low back pain, which we defined as a score of > 5 on the Roland-Morris Disability Questionnaire (RMDQ)  aged>65 years old history of trauma radicular pain, which we defined as pain radiating below the gluteal folds history of vertebral tumor or metastasis patients who were pregnant or lactating unavailable for follow-up with allergy or contraindication to the investigational medications chronic analgesic use autoimmune diseases or inflammatory rheumatic disorders cardiopulmonary restrictions
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 4.0-7.0,  Pulp Disease, Dental Medically free children who will be able and cooperative in all steps of the study. 2 Asymptomatic primary molars with a deep carious lesion. 3 Vital pulp due to dental caries with no clinical sign of pulpal degeneration (spontaneous pain, fistula, mobility) prior to treatment. 3 Preliminary radiographs indicating absence of pathologic internal or external root resorption, or any evidence of inter-radicular bone destruction. 4 Absence of pre-operative pain or they will only have a short-term pain. 5 No tenderness to percussion. 6-Age ranging 4-6 years  Excessive bleeding during pulp amputation. 2 Non vital teeth. 3 -History of spontaneous or prolonged pain. 4 Swelling, tenderness, to percussion or palpation, or pathologic mobility. 5 pre-operative radiographic pathology such as resorption (internal, external); periradicular or furcation radiolucency, or a widened periodontal ligament space. 6 Parent or guardians who refuse participating in the study
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 20.0-60.0,  Bone Marrow Stimulating Modified Suture Bridge Arthroscopy confirmed small to medium rotator cuff injury The data of preoperative functional examination were complete Unilateral rotator cuff injury Clinical follow-up can be completed  Anterior superior rotator cuff injury with simple subscapular injury or combined subscapular injury Previous shoulder surgery (incision or arthroscopy) Combined with diseases of other parts of the same limb Combined with Bankart injury, acromioclavicular joint disease, greater tuberosity fracture, glenoid fracture and so on Bilateral onset Unable or unwilling to receive clinical follow-up